Thursday, June 18, 2026
🇪🇺 EMA
Global Pharma Tech pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High GENERAL CONCLUDED

Global Pharma Tech — 2026 — Radisson Blu Hotel, London Heathrow, London, UK

Global Medical Health & Pharmaceutical Industry Conference 2026 brings together doctors, scientists, pharma experts, and healthcare leaders to explore medical innovations, drug development, biotechnology, and clinical research. Join us in 2026 for expert sessions, networking, and

Radisson Blu Hotel, London Heathrow, London, UK May 18 – May 19, 2026
500+ Attendees
11 Presentations
3 Companies
All Events

Presentation data updated Jun 13, 2026, 5:36 AM UTC

Nova Event Impact Score
63 /100
  • Media coverage 20/20
  • Speaker quality 15/20
  • Pipeline relevance 2/20
  • Historical influence 20/20
  • Company participation 6/20

Key Takeaways

Key Themes

generalNot specifiedPipeline announcementsPartnership deals

Key Companies

AstraZenecaMerck & Co.BioPharma Corp

Key Markets

Europe

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

LATE-BREAKER

AstraZeneca Phase 3 data readout in oncology (H1 2026)

AstraZeneca Phase Iii oncology
Company at this event →
INVESTOR IMPACT: ★★★★★ 5/5
LATE-BREAKER

AstraZeneca Phase 3 data readout in H2 2026

AstraZeneca Phase Iii oncology
Company at this event →
INVESTOR IMPACT: ★★★★★ 5/5
ORAL Jun 1

Solid tumour data readouts outline Merck & Co's oncology prowess

Merck & Co. Phase Iii solid tumours
Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
PLENARY

Next-generation GLP-1 drug data readout in weight loss and T2DM

Phase Iii weight loss, type 2 diabetes mellitus
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL

ABCD-123 Phase 3 interim analysis in obesity

BioPharma Corp Phase Iii obesity
Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL

Key readouts in infectious disease from first half of 2026

Phase Iii infectious disease
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL Jun 2

Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026

Phase Ii CNS tumours
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL

Targeted protein degrader data readout in cancer

Phase Ii cancer
INVESTOR IMPACT: ★★☆☆☆ 2/5
POSTER

Key readouts in rare diseases from first half of 2026

Phase Iii rare diseases
INVESTOR IMPACT: ★★☆☆☆ 2/5
POSTER

Key data readout for EFG-456 in type 2 diabetes mellitus

Merck & Co. Phase Ii type 2 diabetes mellitus
Company at this event →
INVESTOR IMPACT: ★☆☆☆☆ 1/5
SYMPOSIUM

AI-enabled drug discovery program outcomes from emerging biopharma